[ET Net News Agency, 18 March 2024] UBS raised the target price for SKB Bio (06990) to
HKD180.9 from HKD131.9 and maintained the "buy" rating.
The research house said it believes progress is being made in enabling SKB264 to target
a wider patient pool, with best-in-class potential. (RC)